Download pdf
Review of the application of CRISPR/Cas9 in axon regeneration
- 1 College of Life Sciences, Sichuan University, Sichuan, China
* Author to whom correspondence should be addressed.
Abstract
Neurological mechanistic or pathologic damage is often accompanied by neuronal loss. Although this loss is universally considered as irreversible, nervous system possessing a series of compensatory self-repair mechanisms after injury, one is axon regeneration. However, they are restricted by alterations in the microenvironment and multiple suppressors. Therefore, enhancing axonal regenerative capacity to improve plasticity after central nervous system injury has become a critical issue. Previous studies have shown high feasibility and application value of CRISPR/Cas9 in promoting neuronal axon regeneration. This article aims at evaluating the applicability and effectiveness of CRISPR/Cas9 and its derivative method, CRISPR activation system, when it comes to treating central nervous system injuries. Three main routes were reviewed here, including large-scale screening of related genes in vivo, promotion of endogenous neurotrophic factor expression and induction of reprogramming glial cells into neurons. Besides, considering the delay in protein knockdown with the Cas9 system and other shortcomings, its potential application such as improving the local microenvironment post-injury should not be neglected.
Keywords
CRISPR/Cas9, Neural Injury, Axon Regeneration.
[1]. Lindborg, J A, Tran, N M, Chenette, D M, DeLuca, K, Foli, Y, Kannan, R, Sekine, Y, Wang, X, Wollan, M, Kim, I-J, Sanes, J R and Strittmatter, S M (2021). Optic nerve regeneration screen identifies multiple genes restricting adult neural repair. CELL REP, 34(9) 108777. https://doi.org/10.1016/j.celrep.2021.108777
[2]. Tian, F, Cheng, Y, Zhou, S, Wang, Q, Monavarfeshani, A, Gao, K, Jiang, W, Kawaguchi, R, Wang, Q, Tang, M, Donahue, R, Meng, H, Zhang, Y, Jacobi, A, Yan, W, Yin, J, Cai, X, Yang, Z, Hegarty, S, Stanicka, J, Dmitriev, P, Taub, D, Zhu, J, Woolf, C J, Sanes, J R, Geschwind, D H and He, Z (2022). Core transcription programs controlling injury-induced neurodegeneration of retinal ganglion cells. NEURON, 110(16) 2607-24. https://doi.org/10.1016/j.neuron.2022.06.003
[3]. Keatinge, M, Tsarouchas, T M, Munir, T, Porter, N J, Larraz, J, Gianni, D, Tsai, H-H, Becker, C G, Lyons, D A and Becker, T (2021). CRISPR gRNA phenotypic screening in zebrafish reveals pro-regenerative genes in spinal cord injury. PLOS GENET, 17(4) e1009515. https://doi.org/10.1371/journal.pgen.1009515
[4]. Callif, B L, Maunze, B, Krueger, N L, Simpson, M T and Blackmore, M G (2017). The application of CRISPR technology to high content screening in primary neurons. MOL CELL NEUROSCI, 80 170-9. https://doi.org/10.1016/j.mcn.2017.01.003
[5]. Zhou, M, Tao, X, Sui, M, Cui, M, Liu, D, Wang, B, Wang, T, Zheng, Y, Luo, J, Mu, Y, Wan, F, Zhu, L-Q and Zhang, B (2021). Reprogramming astrocytes to motor neurons by activation of endogenous Ngn2 and Isl1. STEM CELL REP, 16(7) 1777-91. https://doi.org/10.1016/j.stemcr.2021.05.020
[6]. Savell, K E, Bach, S V, Zipperly, M E, Revanna, J S, Goska, N A, Tuscher, J J, Duke, C G, Sultan, F A, Burke, J N, Williams, D, Ianov, L and Day, J J (2019). A Neuron-Optimized CRISPR/dCas9 Activation System for Robust and Specific Gene Regulation. ENEURO, 6(1) 0495-18. https://doi.org/10.1523/eneuro.0495-18.2019
[7]. Xie, L, Yin, Y and Benowitz, L (2021). Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy. P NATL ACAD SCI USA, 118(9) e2017282118. https://doi.org/10.1073/pnas.2017282118
[8]. Zhou, H, Su, J, Hu, X, Zhou, C, Li, H, Chen, Z, Xiao, Q, Wang, B, Wu, W, Sun, Y, Zhou, Y, Tang, C, Liu, F, Wang, L, Feng, C, Liu, M, Li, S, Zhang, Y, Xu, H, Yao, H, Shi, L and Yang, H (2020). Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. CELL, 181(3) 590-603.e16. https://doi.org/10.1016/j.cell.2020.03.024
[9]. Lee, S-K and Pfaff, S L (2001). Transcriptional networks regulating neuronal identity in the developing spinal cord. NAT NEUROSCI, 4(11) 1183-91. https://doi.org/10.1038/nn750
[10]. Jo, A Y, Park, C-H, Aizawa, S and Lee, S-H (2007). Contrasting and brain region-specific roles of neurogenin2 and mash1 in GABAergic neuron differentiation in vitro. EXP CELL RES, 313(19) 4066-81. https://doi.org/10.1016/j.yexcr.2007.08.026
[11]. Son, Esther Y, Ichida, Justin K, Wainger, Brian J, Toma, Jeremy S, Rafuse, Victor F, Woolf, Clifford J and Eggan, K (2011). Conversion of Mouse and Human Fibroblasts into Functional Spinal Motor Neurons. CELL STEM CELL, 9(3) 205-18. https://doi.org/10.1016/j.stem.2011.07.014
[12]. Klinkovskij, A, Shepelev, M, Isaakyan, Y, Aniskin, D and Ulasov, I (2023). Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy. BIOMEDICINES, 11(12) 3333. https://doi.org/10.3390/biomedicines11123333
[13]. Yang, S-G, Wang, X-W, Qian, C and Zhou, F-Q (2022). Reprogramming neurons for regeneration: The fountain of youth. PROG NEUROBIOL, 214 102284. https://doi.org/10.1016/j.pneurobio.2022.102284
[14]. Keefe, K M, Sheikh, I S and Smith, G M (2017). Targeting Neurotrophins to Specific Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of Spinal Cord Injury. Int J Mol Sci, 18(3) 548. https://doi.org/10.3390/ijms18030548
Cite this article
Bian,Y. (2024). Review of the application of CRISPR/Cas9 in axon regeneration. Theoretical and Natural Science,60,41-45.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).